Exelixis (EXEL) Expected to Announce Quarterly Earnings on Thursday

Exelixis (NASDAQ:EXEL) is expected to be releasing its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to announce earnings of $0.8870 per share and revenue of $646.51 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, October 29, 2026 at 5:00 PM ET.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.06. The business had revenue of $628.69 million during the quarter, compared to analyst estimates of $636.40 million. Exelixis had a return on equity of 42.17% and a net margin of 35.33%. Exelixis’s revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.75 EPS. On average, analysts expect Exelixis to post $3.19 EPS for the current fiscal year and $3.71 EPS for the next fiscal year.

Exelixis Price Performance

EXEL stock opened at $65.11 on Tuesday. The company has a market cap of $16.13 billion, a P/E ratio of 20.47, a price-to-earnings-growth ratio of 1.81 and a beta of 0.47. Exelixis has a 1 year low of $36.00 and a 1 year high of $65.59. The stock’s fifty day moving average price is $58.31 and its 200-day moving average price is $50.48.

Analysts Set New Price Targets

Several research analysts have weighed in on EXEL shares. William Blair reiterated an “outperform” rating on shares of Exelixis in a research report on Friday, September 11th. UBS Group set a $55.00 price objective on Exelixis in a research note on Monday, August 3rd. Wall Street Zen raised Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Weiss Ratings raised Exelixis from a “buy (a-)” rating to a “buy (a)” rating in a research report on Thursday, October 8th. Finally, Citigroup reiterated a “market outperform” rating on shares of Exelixis in a research note on Monday, October 19th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $51.50.

Insider Buying and Selling at Exelixis

In related news, Director Mary Beckerle sold 9,812 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $53.66, for a total transaction of $526,511.92. Following the completion of the transaction, the director directly owned 16,079 shares of the company’s stock, valued at approximately $862,799.14. This trade represents a 37.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.60% of the company’s stock.

About Exelixis

Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer and other serious diseases. The company’s research programs center primarily on targeted therapies, including treatments designed to inhibit signaling pathways involved in tumor growth and progression.

Exelixis’ lead product is CABOMETYX (cabozantinib), an oral medicine approved in the United States for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer.